Data from the Phase 1 healthy volunteer study of NEU-411 will be presented at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™), taking place April 1-5 in Vienna.
Financing led by funds managed by Blue Owl Capital; Senior Managing Director Kevin Raidy joins Latigo’s board
LTG-001 demonstrated favorable safety and tolerability profile with predictable pharmacokinetics in Phase 1 trial
Capsida to receive a $40 million license payment and is eligible for additional milestones and royalties
Westlake BioPartners leads $30 million Series A extension, bringing the startup’s total committed capital to $180 million
Data to be featured as oral and poster presentations at American Epilepsy Society 2024 Annual Meeting
Acquisition of Kate Therapeutics enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation
Former Horizon Therapeutics chairman & CEO brings 30 years of biopharmaceutical industry experience
Digital biomarker to enhance precision, reduce patient burden and boost efficiency of global Phase 2 trial of NEU-411 in early Parkinson’s disease
NEU-411, a brain-penetrant, potent and selective kinase inhibitor, has potential to slow disease progression in up to 30% of people with LRRK2-driven Parkinson’s disease
